Advances in Treatment Options for Psoriasis

Sudesh S Raju*

Psoriasis is a skin disease that is evidenced primarily by plaques which can be seen throughout the body. Genetic predisposition that combines with an environmental trigger of the immune system is believed to be the root cause of psoriasis. This leads to signaling factors which coordinate the progression of inflammation and psoriatic plaques. Psoriatic patients commonly use topical agents, phototherapy, and systemic agents; however, biological therapies have become increasingly popular. This is primarily due to recent advances in the study of psoriasis which have shown that monoclonal antibodies and dimeric fusion proteins inhibit key signaling molecules within the inflammatory cascade such as TNFa, IL-12 and IL-23. This article reviews the advances made to understand the role of TNFain the progression of psoriasis, discusses treatment options such as topical agents, phototherapy and systemic agents, and then compares a variety of monoclonal antibodies and dimeric fusion proteins as biological therapies.

Keywords: Psoriasis; Plaques; TNFa; IL-12; IL-23; Topical agents; Phototherapy; Systemic agents; Biologic therapies; Monoclonal antibodies; Dimeric fusion proteins; Etanercept; Adalimumab; Infliximab; Golimumab; Certolizumab pegol; Ustekinumab

Published on: Mar 21, 2015 Pages: 1-6

Full Text PDF Full Text HTML DOI: 10.17352/2455-8605.000001
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat